Nov 28
|
These 2 Stocks Are Falling in a Fading Rally
|
Nov 28
|
UPDATE 2-November rally in European stocks stalls after comments from ECB officials
|
Nov 28
|
argenx Reports Topline Results from ADVANCE-SC Study of VYVGART Hytrulo in Primary Immune Thrombocytopenia
|
Oct 5
|
IQVIA (IQV) and argenx Partner to Advance Autoimmune Care
|
Sep 21
|
argenx Announces VYVGART (efgartigimod alfa) Authorized for Sale by Health Canada for Generalized Myasthenia Gravis
|
Sep 17
|
New S&P 500 Entrant Airbnb And DKNG Lead 5 Stocks Near Buy Points
|
Sep 15
|
How IBD Stock Of The Day Argenx, A Top-Notch Biotech, Is Dominating — With One Drug
|
Sep 15
|
argenx Announces Positive CHMP Opinion for Subcutaneous Efgartigimod for Generalized Myasthenia Gravis
|
Aug 9
|
Halozyme (HALO) Q2 Earnings & Revenues Beat, 2023 View Raised
|